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Our aim was to examine the effects of aqueous extracts of fermented (CFE) and non-fermented (CNFE)
¨copoazú¨ (fruit of Theobroma grandiflorum) seeds against ischemia-reperfusion injury. Isolated rat hearts
were submitted to 30 min of global ischemia (GI) and 60 min of reperfusion (R). Other hearts received CFE
or CNFE in absence or in presence of L-NAME (a nitric oxide synthase inhibitor). Infarct size (IS) and post-
ischemic myocardial function (PMF) were measured. Lipid peroxidation, reduced glutathione (GSH) and
the expression of phosphorylated forms of eNOS, Akt, GSK-3b and PKCe were assessed. The response of
isolated mitochondria to Ca2+ (MR) was also determined. CFE but not CNFE decreased IS, increased
PMF and the expression of P-eNOS, P-Akt, P-GSK-3b and P-PKCe, partially preserved GSH and improved
MR. These effects were lost in presence of L-NAME.
These data demonstrate that the acute treatment with CFE protects the heart against ischemia-
reperfusion damage through NOS-dependent mechanisms.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Cardiovascular diseases and ischemic heart disease in particu-
lar, remain the leading cause of death and a significant cause of
long-term morbidity worldwide. Although reperfusion is an abso-
lute criterion for the survival of ischemic tissues, the notion has
developed that it is not without hazard, and reperfusion-induced
pathological changes may occur and further aggravate the previ-
ously ischemia-induced damage. An inadequate perfusion of myo-
cardium despite removal of coronary artery occlusion, defined as
n¨o-reflow phenomenon¨, is one of the consequences to revascular-
ization that causes left ventricular dysfunction, and even cardiac
death (Chan et al., 2012).
Oxidative stress- imbalance of reactive oxygen species (ROS)
production and antioxidants in favor of the former- and calcium
overload appear as the most important contributors to the
reperfusion injury (Das, 2001). Both factors impact on mitochon-
dria promoting the formation and/or opening of mitochondrialpermeability transition pore (mPTP) leading to cell death
(Halestrap, Clarke, & Javadov, 2004).
The relationship between dietary factors and coronary heart
disease has been and remains a matter of intense study and debate.
Several studies show that an increase in fruit and vegetable con-
sumption promotes cardiovascular health and reduces the
ischemic stroke, the ischemic heart disease mortality and cardio-
vascular events (Gardener et al., 2011; Hlebowicz et al., 2013).
At experimental level, much attention has been focused on the
beneficial actions against ischemia-reperfusion alterations
achieved by plant extracts containing the polyphenols as predom-
inant ingredients (Ma et al., 2013; Sakanashi et al., 2013;
Saravanan, Ponmurugan, Sathiyavathi, Vadivukkarasi, &
Sengottuvelu, 2013). In this sense, we recently showed that the
acute treatment with an extract of Teobroma cocoa (González
Arbeláez et al., 2016) was able to limit the infarct size and mPTP
opening through nitric oxide synthase (NOS) activation by reperfu-
sion injury salvage kinases (RISK) pathways.
Theobroma grandiflorum is specie from the Amazon region that
belongs to the Malvaceae family, as the cocoa tree (Theobroma
cacao). The fruit pulp is used in the industry for candy, ice cream,
liquor, and juice production while the seeds are used for the
manufacturing of a product similar to chocolate called¨cupulate¨.
J.C. Fantinelli et al. / Journal of Functional Foods 34 (2017) 470–477 471Phytochemical studies show that the seeds and pulp of ¨copoazú¨
contain flavone, flavan-3-ols and proanthocyanidin as principal
polyphenols (Pugliese, Tomas-Barberan, Truchado, & Genovese,
2013; Yang et al., 2003). There are scarce studies about ¨copoazú¨
and these are mainly focused on the fruit pulp (Gonçalves, Lajolo,
& Genovese, 2010). Thus, it was previously demonstrated that daily
administration of ¨copoazú¨ liquors to diabetic rats ameliorated
body weight gain, improved the plasma antioxidant capacity and
reduced lipid peroxidation (Pinent et al., 2016). Recently, the
antioxidant effects of a proanthocyanidin-rich extract from
¨ copoazú¨ seeds in intestinal cells were shown (de Oliveira &
Genovese, 2013). However, the potential benefits against
ischemia-reperfusion injury of the chocolate-like product obtained
from ¨copoazú¨ seeds have not yet been explored.
The present study was designed to (i) evaluate, in isolated and
Langendorff perfused rat heart, the effects of c¨opoazú¨ seeds aque-
ous extracts obtained at time 0 and after 10 days of traditional fer-
mentation, against ischemia-reperfusion injury and (ii) identify the
intracellular cascades responsible for the cardiac effects achieved
by the extracts.2. Materials and methods
2.1. Plant material
The fruit of Teobroma grandiflorum (copoazú), constitutes the
material used for the fermentation in this research. Mature fruit
were collected at the Center for Research of University of Amazonia
CIMAZ-Macagual (voucher specimen number HUAZ 9030) located
in the department of Caquetá, Colombia.2.2. Fermentation process
The maceration was performed in the traditional fashion,
punching 800 grams of ¨copoazú¨ seeds with 100% of pulp and the
fermentation was carried out using baskets placed in the form of
a ladder. The material was transferred from one basket to another
and this removal was performed every 24 h after the start of the
process for 10 days. After that the seeds were dried, toasted and
crushed (Krysiak, 2006).2.3. Preparation of c¨opoazú¨ extracts
50 g of c¨opoazú¨ seeds obtained at 0 (CNFE) and 10 days (CFE)
of fermentation process were solubilized in aqua and cooked for
20 min. Both aqueous extracts were filtered, lyophilized, and main-
tained at 30 C until used.2.4. HPLC analysis
HPLC-DAD analysis was performed on a Shimadzu LC-2010HT
system equipped with a pump LC-2010AHT, UV Detector LC-
2010AHT, autosampler LC2010 HT, and column RP-C18
(150  3 mm, 4 lm, Restek-Pinnacle). The data were collected
and processed with the software LC- Solutions (Shimadzu). The
experimental protocol was suggested by Hatzidimitriou et al.
(2007) with some modifications. The eluting system used was:
90% solvent A (water with 2% acetic acid, v/v) and 10% solvent B
(acetonitrile) in isocratic conditions. Peak identification was based
on retention times and spiking with standard solutions. Seven-
point calibration curves of theobromine, caffeine, (+)-catechin
and ()-epicatechin were used for quantification. The content of
these compounds was expressed as mg/100 g of dry weight of
the extract.2.5. Determination of total phenols
Total phenolic content was measured by using the Folin-
Ciocalteu method. Results were expressed as mg gallic acid equiv-
alents/100 g of dry weight of the extract (Singleton & Rossi, 1965).
2.6. Total antioxidant activity
2.6.1. Ferric reducing-antioxidant power (FRAP)
The FRAP assay was carried out to determine the reducing abil-
ity of the extracts with a method adapted from Benzie and Strain
(1996). Results were expressed as lmol of ascorbic acid equiva-
lents/100 g of dry weight of the extract.
2.6.2. 1,1-Diphenyl-2-picryl-hydrazyl (DPPH) scavenging activity
The reduction of DPPH stable free radical was determined
according to the modified version of the method described by
Cavin, Hostettmann, Dyatmyko, and Potterat (1998). Results are
expressed in mmol Trolox/100 g of dry weight of the extract.
2.7. Isolated heart preparation
All procedures followed during this investigation were
approved by the Institutional Animal Care and Use Committee
(IACUC) of the Faculty of Medicine, University of La Plata (P-05-
2014).
Hearts from male Wistar rats were isolated and Langendorff
perfused with Ringer’s solution containing (in mmol/L) 118 NaCl,
5.9 KCl, 1.2 MgSO4, 1.35 CaCl2, 20 NaCO3H and 11.0 glucose (gassed
with 95% O2-5% CO2, pH 7.4, 37 C). The conductive tissue in the
atrial septum was damaged with a fine needle to achieve atrioven-
tricular block, and the right ventricle was paced at 280 ± 10 beats/
min. A latex balloon tied to the end of a polyethylene tube was
passed into the left ventricle through the mitral valve; the opposite
end of the tube was then connected to a Statham P23XL pressure
transducer. The balloon was filled with water to provide a left ven-
tricular end-diastolic pressure (LVEDP) of 8–12 mmHg, and this
volume was unchanged for the rest of the experiment. Coronary
perfusion pressure (CPP) was monitored at the point of cannulation
of the aorta and was adjusted to approximately 60–70 mmHg. Cor-
onary flow (CF), which was controlled with a peristaltic pump, was
11 ± 2 ml/min. Left ventricular pressure (LVP) and CPP data were
acquired by using an analog-to-digital converter and acquisition
software (Chart V4.2.3 AD Instruments).
2.7.1. Experimental protocols
After 20 min of stabilization, the following experimental proto-
cols were performed (Fig. 1):
Non-ischemic control hearts (NIC; n = 7): Hearts were perfused
for 110 min without any treatment.
Ischemic control hearts (IC, n = 8): Hearts were subjected to
30 min of normothermic global ischemia followed by 60 min of
reperfusion. Global ischemia was induced by stopping the per-
fusate inflow line, and the heart was placed in a saline bath held
at 37 C.
Copoazú non-fermented extract (CNFE n = 7): Hearts were trea-
ted during the first 10 min of reperfusion with a dose of 0.30 mg/
min of CNFE.
Copoazú fermented extract (CFE n = 8): Hearts were treated
during the first 10 min of reperfusion with a dose of 0.30 mg/min
of CFE. The final concentration in the perfusate was 30 mg/ml.
L-NAME (n = 7): Hearts received 1 mM of LG nitro-L-arginine
methyl ester (L-NAME) -a non-selective nitric oxide synthase
(NOS) inhibitor- from 10 min before ischemia and during all the
reperfusion time.
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Fig. 1. Scheme of the experimental protocols. NIC: non-ischemic control; IC:
ischemic control; CNFE: copoazú non-fermented extract; CFE: copoazú fermented
extract; L-NAME: LG-nitroL-arginine methyl ester, inhibitor of NOS and L-NAME
+ CFE.
Table 1
Content of phenolic compounds and antioxidant activity of aqueousextracts of
copoazú.
CNFE CFE
Phenolic compounds
Total phenols (mg GA/100 g) 1216 ± 59 189 ± 3**
Catechin (mg/100 g) 6.2 ± 0.7 3.6 ± 0.4**
Epicatechin (mg/100 g) 1.8 ± 0.2 1.0 ± 0.1**
Theobromine (mg/100 g) 2.7 ± 0.3 1.6 ± 0.2**
Caffeine (mg/100 g) 3.6 ± 0.4 2.1 ± 0.2**
Antioxidant activity
FRAP (lmol AA/100 g) 920 ± 130 130 ± 2**
DPPH (lmol TROLOX/100 g) 805 ± 97 144 ± 3**
GA: Gallic acid; FRAP: Ferric reducing ability of plasma; AA: Ascorbic acid; DPPH: a,
a-diphenyl-b-picrylhydrazyl.
** p < 0.01.
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Fig. 2. Infarct size (IS), expressed as a percentage of risk area, in ischemic control
(IC) and in hearts treated with aqueous extracts of copoazú fermented (CFE) and
non-fermented (CFE) or L-NAME, inhibitor of NOS and the combination of L-NAME
+ CFE. Observe that CFE treatment but not CNFE decreased the IS obtained in IC
hearts and that this action was abolished by L-NAME treatment. *p < 0.05 vs. IC;
#p < 0.05 vs. CFE.
472 J.C. Fantinelli et al. / Journal of Functional Foods 34 (2017) 470–477L-NAME + CFE (n = 7): Hearts received L-NAME in a similar
manner than L-NAME group and CP was administered at the time
and dose above indicated.
2.7.2. Infarct size determination
Infarct size was assessed by the widely validated triphenyltetra-
zolium chloride (TTC) staining technique (Fishbein et al., 1981).
This technique relies on the ability of dehydrogenase enzymes
and cofactors in the tissue to react with tetrazolium salt to form
a formazan pigment (red). It is a recognized method to discrimi-
nate between dead and viable tissue. At the end of reperfusion,
atrial and right ventricular tissues were excised and left ventricle
(LV) was frozen. The freeze LV was cut into six transverse slices,
which were incubated for 5 min at 37 C in a 1% solution of TTC.
To measure myocardial infarction, the slices were weighed and
scanned. The infarcted (pale) and viable ischemic/reperfused
(red) areas were measured by computed planimetry (Scion Image
1.62; Scion Corp., Frederick, Maryland, USA). Infarct weights were
calculated as (A1 W1) + (A2 W2) + (A3 W3) + (A4 W4)
+ (A5 W5) + (A6 W6), where A is the area of infarct for the slice
and W is the weight of the respective section. Infarct size was
expressed as a percentage of total area (area at risk, AR).
2.7.3. Systolic and diastolic function
The systolic function was assessed by the left ventricular devel-
oped pressure (LVDP)- calculated by subtracting LVEDP from the
left ventricular (LV) peak pressure values- and the maximal veloc-
ity of rise of LVP (+dP/dtmax). The diastolic function was evaluated
through the maximal velocity of decrease of LVP (dP/dtmax) and
LVEDP.
2.7.4. Coronary resistance (CR)
CR was calculated as a quotient between CPP and CF.
2.7.5. Assessment of lipid peroxidation
We used the TBARS spectroscopic technique to evaluate lipid
peroxidation. At the end of the reperfusion period, a portion of
LV was homogenized in physiological saline solution and cen-
trifuged at 770g to allow measuring TBARS in the supernatant.
Absorbance at 535 nm was measured and TBARS expressed innmol/mg protein using an extinction coefficient of
1.56  105 M1 cm1 (Buege & Aust, 1974).
2.7.6. Reduced glutathione
GSH was determined by Ellman’s method, which is based on the
reaction of non-protein sulfhydryl groups with 5,50-dithiobis (2-
nitrobenzoic acid) to give a compound that absorbs at 412 nm.
GSH levels were expressed as lg/mg protein (Sedlak & Lindsay,
1968).
2.7.7. Immunoblotting
Other portion of LV was homogenized and cytosolic fraction
was isolated by differential centrifugation. Briefly, LV were homog-
enized in ice-cold RIPA buffer (300 mmol/L sacarosa, 1 mmol/L
DTT, 4 mmol/L EGTA, 20 mmol/L Tris pH 7.4, 1% Triton X, 10% pro-
tease cocktail, 25 lmol/L FNa, 1 lmol/L ortovanadate) and cen-
trifuged at 12,000g for 15 min at 4 C. From supernatant proteins
(60 mg) were resolved on SDS-PAGE and transferred to PVDF mem-
brane (2 h). Equal loading of samples was confirmed by Ponceau S
staining. Membranes were blocked with 5% non-fat milk in Tris-
buffered saline (pH 7.5) containing 0.1 % Tween (TBS-T), and
probed overnight at 4 C with antibodies against phosphorylated
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Fig. 3. Time course of left ventricular developed pressure (LVDP, A panel), maximal velocity of rise of left ventricular pressure (+dP/dtmax, B panel), maximal velocity of
decrease of left ventricular pressure (dP/dtmax, C panel), left ventricular end diastolic pressure (LVEDP, D panel), and reperfusion changes of coronary resistance (DCR, E
panel), in ischemic control (IC) and in hearts treated with CNFE, CFE, L-NAME or L-NAME + CFE. Note that CFE but not CNFE, significantly improved the postischemic recovery
of myocardial function, attenuated the cardiac stiffness and annulled the increase of CR detected in IC hearts. The NOS blockade with L-NAME abolished these beneficial
actions of CFE. *p < 0.05 vs. IC.
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(1:1000, Santa Cruz Biotechnology), PKCe ((1:1000, Santa Cruz
Biotechnology) and eNOS-Ser1177 (1:1000, Sigma-Aldrich). Mem-
branes were washed four times for 10 min in TBS-T prior to addi-
tion of anti-rabbit secondary antibody (1:5000, Santa Cruz
Biotechnology) and protein bands were analysed by a chemilumi-
nescent system (ECL Plus; GE Healthcare Life Sciences). GAPDH sig-
nal was used as a loading control.2.8. Isolation of mitochondria
LV of non-perfused rat hearts were washed and homogenized in
ice-cold isolation solution (S) consisting of 75 mM sucrose,
225 mM mannitol, and 0.01 mM EGTA neutralized with Trizma
buffer at pH 7.4. After the tissue pieces were settled, the entire
supernatant was discarded and fresh IS (5 mL) was added, and
the mixture was transferred to a hand homogenizer. Proteinase
(0.8 mg, bacterial, type XXIV, Sigma-Aldrich, formerly called
Nagarse) was added just before starting the homogenizationprocedure. The whole homogenization procedure took no longer
than 14 min in two steps of 7 min each (with 5 mL addition of fresh
S each). The homogenate was carefully transferred after each step
to a polycarbonate centrifuge tube. After 5 min of 480g of centrifu-
gation to discard unbroken tissue and debris, the supernatant was
centrifuged at 7700g for 10 min to sediment the mitochondria. The
mitochondrial pellet was washed twice with IS and the last one
with suspension solution (IS without EGTA) at 7700g for 5 min
each.2.8.1. Ca2+-induced mPTP opening
The ability of mitochondria to resist swelling was assessed by
incubating 0.3 mg/mL of isolated mitochondria in a buffer contain-
ing (in mmol/L): 120 KCl, 20 MOPS, 10 Tris HCl, and 5 KH2PO4
adjusted to pH = 7.4. After 5-min preincubation, the mitochondria
energized with the addition of 5 mmol/L succinate were induced to
swell with 100 lmol/L CaCl2. If mPTP is open in the presence of
Ca2+ loading, solutes will be free to enter the inner matrix, causing
the mitochondria to swell. These changes are observed as
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controlled Hitachi F4500 spectrofluorometer operating with con-
tinuous stirring at excitation and emission wavelengths of
520 nm (Facundo, de Paula, & Kowaltowski, 2007). LSD was calcu-
lated for each sample by taking the difference of scattered light
between before and after the addition of CaCl2. LSD was assessed
in samples without any treatment and in those treated with CFE
(7.5 mg/mL), L-NAME (1 mM) and the combination of both (L-
NAME + CFE). In order to relate mPTP opening to decreased light
scattering, we added cyclosporine A 0.5 mM to inhibit mPTP or
abolish any observed reduction.
2.9. Statistical analysis
Data were expressed as means ± SD. Statistical analysis was
performed by one-way analysis of variance (ANOVA) followed by
the Newman-Keul’s post-test used for multiple comparisons
among groups. Values of p < 0.05 were considered to indicate sta-
tistical significance.3. Results
Table 1 shows the content of phenolic compounds and antioxi-
dant activity of both ¨copoazú¨ extracts (CNFE and CFE). The datashow that CFE, probably as a consequence of the fermentation pro-
cess, has a smaller amount of catechin, epicatechin, theobromine
and caffeine and a lesser antioxidant activity than CNFE.
Thirty min of global ischemia followed by 60 min of reperfusion
caused an infarct size (IS) of 30% of risk area. This value was not
modified by the addition of CNFE or LG-nitro-L-arginine methyl
ester (L-NAME) but a significant reduction was observed when
CFE 30 lg/mL was added to the perfusate (Fig. 2). This beneficial
effect was annulled by L-NAME treatment.
The time course of contractility during ischemia and reperfu-
sion of all experimental groups is shown in Fig. 3. In IC hearts, LVDP
decreased to 15 ± 4% from pre-ischemic value at the end of the
reperfusion period. The treatment with CFE but not with CNFE
improved post-ischemic recovery of myocardial function. At the
end of reperfusion, LVDP reached a value of approximately 50%
of pre-ischemic value (Fig. 3, A panel). A similar pattern was
observed when + dP/dtmax was analysed (Fig. 3, B panel). An
increase of -dP/dtmax was also evident after CFE treatment (Fig. 3,
C panel). The LVEDP (an index of diastolic stiffness) was approxi-
mately 10 mmHg at the end of stabilization period and signifi-
cantly increased during ischemia-reperfusion reaching a value of
approximately 50 mmHg at the end of reperfusion. After CNFE or
L-NAME addition, LVEDP acquired higher values than those
observed in IC. However, the treatment with CFE significantly
reduced the LVEDP values detected in untreated hearts (Fig. 3, D
panel). These beneficial effects were lost when NO synthesis was
inhibited by L-NAME. Ischemic contracture was not modified by
CFE but increased in presence of L-NAME.
No-reflow phenomenon, a disorder that interrupts the microcir-
culation during reperfusion, is also involved in reperfusion injury
(Kloner, 2011). In our experimental preparation, at constant coro-
nary flow (CF), changes of coronary perfusion pressure (CPP) pro-
duce changes in coronary resistance (CR). These changes are
indicating the incidence of treatments on vasomotor tone. The
ischemia-reperfusion produced an increase of CR leading to an
inadequate coronary perfusion endangering myocardial cell life
and promoting cell death. This increase was not observed after
CFE treatment indicating than an improving of post-ischemic coro-
nary perfusion occurred in presence of the extract. This beneficial
action was abolished by NOS inhibition with L-NAME, highlighting
the NO-mediated CFE vasodilator effect (Fig. 3, E panel).
Untreated hearts (IC) also showed a diminution of GSH level
and an increase of TBARS. The treatment with CFE partially pre-
served the GSH content and did not modify the TBARS concentra-
tion. The beneficial action on GSH was attenuated when CFE was
administered in presence of L-NAME (Fig. 4).
A significant increase of the expression of phosphorylated forms
of Akt, GSK-3b, e-NOS and PKCe at the end of reperfusion period
was observed in hearts treated with CFE. This increase was signif-
icantly attenuated when CFE was added in presence of L-NAME
(Fig. 5).
Fig. 6 shows typical traces of swelling experiments (A) and the
mean values of light scattering decrease (LSD, B) produced by the
addition of 100 mmol/L Ca2+ to samples of mitochondrial suspen-
sion obtained from untreated and treated hearts. The CFE treat-
ment significantly decreased the LSD produced by Ca2+
(0.26 ± 0.10 vs. 1.40 ± 0.14 a.u.) and L-NAME abolished this change
(0.80 ± 0.10 a.u.). The addition of CsA significantly attenuated the
LSD produced by Ca2+ (0.10 ± 0.02 a.u.) (data not shown).4. Discussion
The present study demonstrates for the first time that the treat-
ment at the onset of reperfusion with ¨copoazú¨ fermented extract
(CFE) limits the infarct size and improves postischemic recovery of
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affected. *p < 0.05 vs. NIC; #p < 0.05 vs. IC; /p < 0.05 vs. CFE.
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mental conditions, the administration of a non-fermented extract
of ¨copoazú¨ did not exert beneficial actions on myocardium.
An improvement of coronary perfusion is an indication of the
protection against ¨non-reflow¨ phenomenon. Previous results sug-
gest that polyphenols are able to improve endothelium-dependent
vasodilation, in which NO plays a crucial role (Andriantsitohaina
et al., 2012). In our experimental preparation, we detected an
attenuation of coronary resistance (vasodilator effect) in hearts
treated with CFE. This effect was abolished when NOS was inhib-
ited by L-NAME. Therefore, this result reinforces the hypothesis
that an increased NO production via eNOS activation achieved by
CFE is an important mechanism contributing to the attenuation
of coronary perfusion post-ischemic deficiency.
Of the various pathological events that lead to ischemia-
reperfusion injury, the abrupt ROS production, the increased
cytosolic calcium and the cross talk between both events play
key roles (Peng & Jou, 2010). Although ROS production occurs in
several cellular locations, the mitochondrial production predomi-
nates in ischemia-reperfusion-mediated oxidant injury in the
heart. Under these conditions, the antioxidant effect should be rel-
evant. In our experiments, the partial preservation of GSH detectedin hearts treated with CFE would be an indication of a lesser ROS
production. What would be the mechanism to explain this possible
ROS diminution? Could it be due to the antioxidant action of the
extract? There is accumulated evidence that show that cardiopro-
tective mechanisms triggered by natural antioxidant go further
than their antioxidant action (Akhlaghi & Bandy, 2009). Examining
our data this premise comes true. The¨in vitro¨ analysis of CFE
shows that the fermentation process, drying and roasting of
¨ copoazú¨ seeds, decreases the total polyphenols content and the
antioxidant activity compared to CNFE. At this point it should be
remembered that fermentation is an old technology used to
improve the useful life and nutritional and organoleptic qualities
of food and to extract its bioactive compounds (Martins et al.,
2011). This process alters the relationship between nutritive and
non-nutritive components of food, affecting the bioactivity and
digestibility of the products (Zhang et al., 2012). In our case, car-
dioprotective actions against ischemia-reperfusion injury were
only detected when CFE was administered. Therefore, we demon-
strated that the product obtained by the fermentation process
was efficient to protect the heart while that unfermented was
not. Moreover, our results are suggesting that the antioxidant
action of CFE is not the principal mechanism responsible of the
0.0
0.3
0.6
0.9
1.2
1.5
1.8
#* 
* 
L-N
AM
E
+ C
FEL-N
AM
E
CF
E
Co
ntr
ol
Li
gh
t s
ca
tte
rin
g 
de
cr
ea
se
 (a
.u
.)
CFE
L-NAME +
CFE
L-NAME
Control
0.25 u.a
Ca2+
A
B
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reperfusion injury. Hence, others mechanisms would be impli-
cated. Thus, the modulation of intracellular signalling pathways
has been long recognized as crucial for cardioprotection being
the mitochondria and specifically the mPTP the end target. The for-
mation/and opening of mPTP is linked to cell death (Halestrap
et al., 2004) and the attenuation of that process promote the cell
survival. In relation to the kinases, Juhaszova et al. (2009) showed
that inhibition/phosphorylation of GSK-3b alters the phosphoryla-
tion of target substrates associated to mPTP thus delaying its open-
ing time. Our data show that CFE increased the level of
phosphorylated form of GSK-3b which was attenuated in presence
of L-NAME.
What kinases are able to phosphorylate GSK-3b? It was previ-
ously recognized that this action is mediated by PI3K/Akt depen-
dent pathway (Tong, Imahashi, Steenbergen, & Murphy, 2002). In
this study the Akt expression followed the same pattern than
GSK-3b, i.e. decreased in IC, increased in CFE treated hearts and
it was attenuated when NOS was inhibited.
On the other hand, it has been previously documented the pro-
tective role of NO during ischemia-reperfusion (Bolli, 2001). This
radical combines with O2 at a very fast rate to form peroxynitrite
(ONOO). NO is produced by nitric oxide synthase (NOS) activated
by phosphorylation. Although there are many potential phospho-rylation sites on the endothelial isoform of NOS (eNOS), function-
ally most is known about the phosphorylation of the Ser1177
residue (induces eNOS activation) and the Thr495 residue (pro-
duces eNOS inhibition). In our experimental conditions, an increase
of eNOSSer1117 phosphorylation was detected in CFE treated com-
pared to untreated hearts and was annulled in presence of L-
NAME. Who activates eNOS? Previously, it was shown that Akt is
able to activate eNOS increasing NO production (Fulton et al.,
1999). Other kinases and phosphatases, such as PKC, ERK1/2, pro-
tein phosphatase 1 and protein phosphatase 2A participate in the
control of eNOS phosphorylation (Dudzinski & Michel, 2007).
Protein kinase C e (PKCe) is a pivotal signalling element in the
myocardial protection against ischemia-reperfusion injury
(Baines, Pass, & Ping, 2001). An essential feature of the activation
of PKCe is its subcellular redistribution. The translocation to speci-
fic subcellular compartments is thought to be an important mech-
anism for PKCe to direct downstream signalling cascades and
orchestrate protection. In this study, we showed an increase of
the phosphorylated form of PKCe in hearts treated with CFE and
a reduction in presence of L-NAME.
The decreased level of Akt and PKCe in presence of L-NAME
could be explained considering the ability of NO/cGMP in the
translocation/activation of PKC (Costa et al., 2005; Ping et al.,
1999) and Akt phosphorylation (Kawasaki et al., 2003). A physical
and functional coupling of PKCe, Akt, and eNOS constituting sig-
nalling modules, as was previously reported (Zhang et al., 2005)
could be contributing to the cardiac protection afforded by CFE.
Mitochondria and specifically the mPTP has received consider-
able attention in the development of cardioprotection. In isolated
mitochondria we observed an attenuation of mPTP response to
Ca2+ after CFE addition. This response was abolished in presence
of L-NAME suggesting that NO plays a crucial role in the protective
effects of CFE on mitochondria. This action could explain the CFE-
evoked infarct size limitation.
Given the complex composition of herbal extracts, the benefi-
cial actions observed in hearts treated with CFE would be the result
of the synergistic action of all components and not attributable
only to polyphenols (Wagner & Ulrich-Merzenich, 2009; Yang
et al., 2014).5. Conclusion
This study demonstrate in an¨ ex vivo¨ heart model that the
treatment only during reperfusion with an aqueous extract of fer-
mented ¨copoazú¨ seeds protects the myocardium against
ischemia-reperfusion injury through Akt/GSK-3b, Akt/NO/Akt,
Akt/NO/PKCe-dependent pathways- in which NO plays a central
role- targeting on mitochondria. Other interesting finding is that
there is no direct relationship between antioxidant effect and car-
dioprotection. Taking into account the growing interest in
designing food-derived tools for health improvement and for pre-
venting and treating several pathologies, the knowledge of the
beneficial effects of ¨copoazú¨ fermented extract may be of great
relevance. However, our findings could not be extrapolled directly
to human. Multiple models including large animals and models
with co-morbidities should be performed prior to clinical
translation.
Since that the combined therapy is used to improve the
patient’s overall health status, the utilization of herbal medicine,
which is considered as a ‘‘multi-target herb” should be optimized.Conflict of interest
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